Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers (for specialized target groups only)

Completion of NDA submission expected in early 2018
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news